In this issue of Blood, Mahe vas et al demonstrate that an immunomodulatory drug or a proteasome inhibitor partnered with dexamethasone can lead to a clinically meaningful improvement in severe cases of scleromyxedema that are refractory to high-dose IV immunoglobulin (IVIG).1 2020 by The American Society of Hematology.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Apr 2020|
ASJC Scopus subject areas
- Cell Biology